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Chapter 1: Introduction 
 Breast cancer is uninhibited cellular growth that occurs within the breast.  Although there 
are many different forms of breast cancer, the most common type of breast cancer found in 
women is ductal carcinoma in situ (DCIS).  DCIS is a noninvasive form of breast cancer where 
malignant cells arise and proliferate within the breast ducts without invasion of the basement 
membrane.  DCIS is a precursor for invasive ductal carcinoma and therefore if left untreated can 
invade the epithelial membranes of the surrounding tissue and becomes an invasive infiltrating 
type of breast cancer (Reynolds, 2013).  Invasive ductal carcinoma may develop in 30 to 50% of 
all DCIS cases (Lee, Vallow, McLaughlin, Hines, & Peterson, 2012).  
Description and Prevalence of the Problem 
 One out of every eight women will be diagnosed with breast cancer.  These statistics 
make it the most frequently diagnosed cancer in women.  The American Cancer Society projects 
that 295,240 breast cancer diagnoses will occur in 2014, this includes invasive and noninvasive 
breast cancer.  The breast cancer mortality rate for 2014 is an estimated 13.6 % making it the 
second leading cause of cancer death in women (American Cancer Society, n.d.).  With statistics 
such as these, it is not hard to comprehend why so much research is being done to find effective 
treatments, preventative measures, or a cure for this disease.  
 Survival rates for breast cancer are determined by the cancer staging at diagnosis.  
Research has show that an earlier diagnosis yields a better outcome.  With the advancements in 
screening technology and treatment, more women are being diagnosed early at a localized stage 
and the average age range is 50 to 60.  Most treatment regimens for breast cancer involve 
surgery, chemotherapy, and radiation.  These modalities are dictated by the National 
Comprehensive Cancer Network (NCCN) guidelines.  Given that these women are being 
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diagnosed at a younger age, the treatments take weeks and months to complete.  This places 
these women with a hardship of treating their cancer while raising children, balancing a career, 
and living life.  Conventional radiation techniques that are the standard of care currently state 
that women must have external beam radiation daily five days a week for an average of six 
weeks.    
 Purpose Statement 
The goal of this research is to assess the efficacy of single-fraction intra-operative 
radiation therapy (IORT) using the Xoft Axxent System at time of breast conserving surgery for 
early stage breast cancer.  PICO: Intra-operative radiation therapy (IORT) using the Xoft Axxent 
eBx System is no worse (non-inferior) that whole breast irradiation when used as stand-alone 
radiation treatment in breast conserving therapy in women with early stage breast cancer.  
Rationale for Review 
The primary efficacy endpoint for this research is to demonstrate that the local recurrence 
rate of intraoperative radiation therapy is non-inferior to external beam radiation.  The potential 
benefits of IORT are; elimination of tumor tissue, decrease the likelihood of recurrence, reduce 
radiation delivered to non-target tissue, accelerated delivery system, reduced treatment time, 
improved cosmetic aesthetics post treatment, and decrease the incident of skin fibrosis. 
Definition of Major Terms 
Breast Cancer- Cancer that forms in the tissue of the breast. 
Breast Conservation Surgery- An operation to remove the breast cancer but not the breast itself. 
Types of breast-conserving surgery include lumpectomy (removal of the lump), quadrantectomy 
(removal of one quarter, or quadrant, of the breast), and segmental mastectomy (removal of the 
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cancer as well as some of the breast tissue around the tumor and the lining over the chest muscles 
below the tumor). Also called breast-sparing surgery (National Cancer Institute, n.d.). 
Ductal Carcinoma in Situ- (DCIS) of the breast is characterized by malignant epithelia cells 
confined to the ductal system of the breast without evidence of invasion through the basement 
membrane into the surrounding tissue. 
Intra-Operative Radiation Therapy- (IORT) is a single fractional dose of radiation that is 
delivered directly to the tumor bed during breast conservation surgery. 
Total Mastectomy- Surgery to remove the entire breast and surrounding lymph tissue.  
Whole Breast Radiation Therapy (WBRT) or External Beam Radiation Therapy (EBRT)- Uses 
high-energy x-ray (linear accelerator) to directly deliver radiation to the tumor. 
Theoretical Framework 
In researching the different treatment options available for breast cancer the theoretical 
framework that seems to assess all aspects of the patient is Betty Neuman’s Systems Model. 
Neuman’s System theory includes the following concepts; a wholistic client, an open system, 
and stressors.  The patient is viewed as a whole, whose body is in constant interaction with the 
with the evolving environment, other people and within themselves (Neuman & Fawcett, 2002).  
The interaction between any of these concepts can induce stress to the patient and disrupt 
wholeness. 
Stressors are viewed as anything that interrupts stability of an individual and posses a risk 
to the body’s normal line of defense.  The individual’s reaction to the stressor is dependent upon 
the time of occurrence, the present and past condition of the individual and the individual’s 
ability to adapt to the stressor.  Stressors may be intra, inter, and extra-personal (Neuman& 
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Fawcett, 2002).  The stressors in regards to breast cancer and cancer treatment are discussed in 
the following paragraphs. 
Intrapersonal stressors are internal environmental forces occurring within the patient.  
Examples of intrapersonal factors in relation to breast cancer that could pose stress to a client are 
the initial diagnosis of cancer and the uncertainty of survival.  The pain associated with surgical 
removal of the cancer and any associated radiation treatments, alteration in body image and 
disruption of the woman’s sexuality. 
Interpersonal stressors are external environmental interaction forces occurring outside the 
client (Neuman & Fawcett, 2002).  Interpersonal stressors related to breast cancer may include 
changes in role expectation within the family unit, or conflicts related to surgery, procedures and 
treatments.  Disruption to daily living by cancer treatment can cause the patient to have increased 
stress and progress to requiring extra energy to adapt to this stressor. 
Extrapersonal factors are external factors or interactions occurring outside of the patient 
at a distant range, (Neuman & Fawcett, 2002).  Hospitalization, frequent trips to the physician, 
and radiation treatment are just a few examples of this type of stressor.   
The ultimate goal of Neuman’s System Models in relation to breast cancer it to help the 
patient deal with the interpersonal, intrapersonal, and extrapersonal stress factors.  Positive 
interaction with any of the stressor will help the patient cope with cancer and promote wellness 
within, which will in turn return the person back to a whole.   
Chapter 2: Literature Review 
 The literature search was accomplished using the CINAHL, Academic Search Premier, 
and MEDLINE databases.  Search words included “breast cancer,” “ductal carcinoma in situ,” 
“Xoft,” and “intraoperative radiation therapy,” during the time period of 2004-2014.  The 
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inclusion criteria for this review were articles that focused on defining breast cancer and ductal 
carcinoma in situ, and the modalities of treatment.  All literature had to be scholarly and peer 
reviewed.  The reference lists of the selected articles were also reviewed and were included.  The 
literature is comprised of 1791 pertinent scholarly articles of breast cancer, types of breast cancer 
and modalities of treatment.  
Once considered to be a rare breast lesion, DCIS now constitutes 20 % of all newly 
diagnosed breast cancer cases.  One case of DCIS will be detected in every 1300 screening 
mammograms (Siziopikou, 2013).  Patients with DCIS can be asymptomatic at the time of 
presentation (mammogram) or present with symptoms as a palpable mass or nipple discharge.  
Prior to the advent of widespread screening mammograms DCIS was diagnosed by surgical 
removal of a suspicious breast mass.  The incidence of DCIS has markedly increased, primarily 
due to improved screening and imaging techniques.  This has led to a shift in disease 
presentation from in the past where patients presented with symptomatology to the current period 
where the disease is detected solely by abnormal mammographic finding (Moran et al., 2012).       
Conventional mammography is the gold standard modality used for annual breast cancer 
screening to detect calcifications as well as any soft tissue changes (Reynolds, 2013).  On a 
mammogram, DCIS appears as clustered microcalcifications.  These calcifications differ in 
density, form and size and are grouped together in linear or segmental arrangements reflecting 
their presence in the ducts (Lee, Vallow, McLaughlin, Hines, & Peterson, 2012). 
There are several risk factors associated with DCIS.  Less educated women had a greater 
cumulative incidence of DCIS than women with a higher education.  Breast cancer registry data 
consistently show that the incidence of DCIS increases until age 65-69 then declines.  According 
to the World Health Organization Collaborative Study on Neoplasia and Steroid Contraceptive 
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there is a significant increase of DCIS in women over the age of 35 that used oral contraceptives. 
Women with four or more children had a 38 % decreased risk of DCIS (Virnig, Shamliyan, 
Tuttle, Kane, & Witt, 2009). 
The management and treatment of DCIS is very controversial for many reasons. There 
are no prospective randomized trails comparing mastectomy, breast conservation with radiation 
and breast conservation without radiation for the treatment of DCIS.  Retrospective data suggest 
survival is similar among all methods of treatment (Lee, Vallow, McLaughlin, Hines, & 
Peterson, 2012). 
As the incidence of DCIS increases, the treatment options continue to evolve.  Traditional 
treatment for DCIS was total mastectomy, which often required cosmetic reconstruction surgery.  
Previous standards of care have transitioned from radical surgery only (total mastectomy) to 
bimodality treatments consisting of breast conservation surgery (BCS) partial mastectomy, 
lumpectomy with external beam radiation treatment (EBRT) (Ash, Williams, Wagman, & 
Forouzannia, 2013).  The modality of treatment is based on type and stage of breast cancer the 
patient has.   
Mastectomy was traditionally the standard of care for DCIS and historical data 
demonstrated the risk of local recurrence post mastectomy is extremely low.  Simple mastectomy 
remains a treatment option however results from the National Surgical Adjuvant Breast and 
Bowel Program (NSABP) B17 study established that breast conservation surgery followed by 
radiation as a standard treatment option for DCIS (Siziopikou, 2013).   
Breast conservation surgery for DCIS combined with external beam radiation therapy can 
reduce the risk of local recurrence but is associated with significant cost.  Treatment modality of 
using EBRT timespan ranges from five to seven weeks and is associated with interruption of 
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daily life and financial burdens.  Transportation to a radiation center, physical limitations and or 
lack of family support may prevent many patients from selecting breast-conserving therapies.  In 
addition, EBRT is associated with potential acute and chronic toxicities to the surrounding 
normal tissue such as dermatitis, soft tissue fibrosis, rib fractures, hyperpigmentation, and 
volume loss of breast tissue in the treated breast and an increase risk of cardiac disease in 
patients with left sided breast cancers (Ash, Williams, Wagman, & Forouzannia, 2013).    
A therapeutic alternative to EBRT would be a treatment that has equivalent efficacy 
while reducing overall toxicity and treatment duration. Intraoperative radiotherapy (IORT) is 
radiotherapy that delivers radiation to the tumor bed during surgical excision of cancerous 
lesions (Reitsamer et al., 2008).  This treatment can reduce or eliminate the need for external 
beam radiation therapy.  This treatment approach has the potential to significantly reduce normal 
tissue toxicity.  IORT avoids radiation to the skin and limits radiation exposure to normal breast 
tissue.  Radiation dose to deep structures, such as heart, ribs and lungs is reduced since IORT 
utilizes electron or low energy x-ray (Ash, Williams, Wagman, & Forouzannia, 2013).  A highly 
favorable aspect of IORT is direct visualization of the target volume need to ensure appropriate 
treatment coverage needed and this visualization reduces the risk of geographic oversight (Sinha, 
2008).  
Ductal carcinoma in situ is a disease with heterogeneous clinical behaviors and successful 
treatment of DCIS requires a multidisciplinary approach.  At the present time no well-established 
studies to direct the change of treatment or to predict the clinical behaviors of DCIS.  Several 
clinical trails such as Xoft and the TARGIT trail are ongoing and show many improved 
strategies for treating breast cancer.   
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Chapter 3: Methods 
Design  
This is a single-arm, historical controlled, non-randomized, non-inferiority study of 
subjects treated with single fraction, intra-operative radiation therapy at the time of breast 
conserving surgery for early stage breast cancer.  This is a multicenter study being conducted at 
The Sara Cannon Cancer Center at Parkridge Medical Center in Chattanooga Tennessee and 
multiple centers across the United States, Spain and Germany.  The Primary Investigator for the 
Sarah Cannon Cancer Center is Dr. Stephen Golder a Radiation Oncologist and Sub Investigator 
is Dr. Laura Witherspoon a specialty train breast surgeon.   
This prospective study is sponsored and monitored by Xoft Axxent eBx Systems.  
Subject that enrolled in this study will be only treated with the Xoft Axxent eBx System at the 
time of breast conserving surgery. 
Population 
 This phase IV clinical trail is currently enrolling up 1,600 to eligible participants in fifty 
centers across the United States and Europe.  The trial period will be ongoing during June 2012 
to June 2014 and will be comprised of females greater than or equal to forty years of age. 
Variables 
The variables under study for this research are the following:  age, sex, biopsy proven 
invasive ductal carcinoma or ductal carcinoma in situ of ipsilateral or bilateral breast with tumors 
less than or equal to 3.0 cm in greatest diameter.  Cosmesis of bilateral breast using the Harvard 
Scale and skin assessment is performed at baseline and during month 6,12, 18, year 2 and then 
annually through 10 year follow up.  The rate and severity of adverse events, disease free and 
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overall all survival rates will be assessed during the ten-year follow up.  Other variables assessed 
were quality of life pre and post treatment.  All these variables were compiled to evaluate the 
success of intervention of Xoft intraoperative radiation therapy for breast cancer. 
Measurements 
 The analysis of the primary endpoint of breast tumor recurrence at five and ten years will 
be done by utilizing a random effects model for joint analysis of survival proportions reported at 
multiple time points during the study.  Patient baseline characteristics for age at enrollment, 
ethnicity, menopausal status, tumor size, grade and classification, prior cancer history, family 
history of breast cancer, pregnancy history, volume of tissue excise and medications will be 
summarized.  These comparisons are presented in order to identify any major baseline site or 
therapy differences that could affects outcomes. 
 Descriptive statistics for continuous variables will consist of the mean, median, standard 
deviation, minimum and maximum values.  When comparisons are presented a Chi-Square test 
for categorical variables, one-way ANOVA for continuous variables will be used or the 
equivalent non-parametric test in the case where there is no identifiable distribution. 
 The Xoft Axxent Electronic Brachytherapy System and balloon applicator and sources 
are FDA cleared.  An independent Data and Safety Monitoring Board will review safety and 
adverse events throughout the duration of the trial. 
Results and Discussion 
How Role Evolved 
I first was made aware about this current research by speaking with Kassie Britton RN 
who is the research coordination with the Sarah Cannon Cancer Center at Parkridge Medical 
Center.  I discussed with her my desire to get involved with some research project and she told 
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me about some research projects going on within her department.  This evolved as a beginning 
point to be involved with the Xoft phase 4 clinical trials for early-staged breast cancer.   
Role as Research Assistant 
As a research assistant for this study I performed chart reviews on patients who were 
diagnosed early stage breast cancer, ductal carcinoma in situ (DCIS) during a three-month period 
of 2014.  I audited and compiled the outcome variables of pre and postoperative visits.  I 
performed over 60 hours reading, interpreting, synthesizing and logging in data.  I also assisted 
the researcher in other ways such as organizing, storing, and filing paperwork for this study.   
I was very fortunate to be able to follow one subject from the first interview for possible 
participation to being involved during her surgical procedure and seeing first hand the 
intraoperative radiation treatment.  At her one month follow up I was able to assess her quality of 
life post surgery and cosmeis of her breast post surgery and post IORT. 
Findings 
This study is still in the collection phase of its findings therefore no findings are available 
to report at this time.  The target enrollment date is completed and subject’s data will be followed 
for a period of ten years.     
Chapter 4: Evaluation 
Overall I learned a great deal from this experience.   This was my first experience with 
research and synthesizing information from charts and interviewing subject for a study.  I found I 
gained more knowledge about breast cancer and cancer treatments.  When I began my chart 
reviews I found I had to look up a lot of information so I could understand what I was reading 
from radiological reports, pathology reports and CT scans.  Just simple terminology was hard to 
interpret at first but the more I became familiar with anatomy of the breast and the various tools 
SAFETY AND EFFICACY OF XOFT  12 
 
being used during the procedures I found I was quicker by the end.  Overall this was a great 
experience and it opened my eyes on how hard it is to conduct research and then to follow 
through with the findings.  This clinical trail has finished its enrollment period and subjects will 
be followed during the next ten years and hopefully this research will aid in the advancement of 
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